SEPTEMBER 12, 2017
Kevin Kunzmann
The fixed-dose combination of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) (Technivie, AbbVie), which is approved to treat HCV genotype 4, was combined with the pangenotypic DAA, sofosbuvir (SOF) (Sovaldi, Gilead), in addition to ribavirin for 12 weeks in patients having genotype 3 with cirrhosis, and with or without ribavirin in type 3 patients without cirrhosis. In addition, the regimen with ribavirin was administered for either 6 or 8 weeks to genotype 2 patients without cirrhosis.
If the regimen without ribavirin proves efficacious, Shafran explained, it would offer a treatment option for many patients unable to tolerate it.
If the regimen without ribavirin proves efficacious, Shafran explained, it would offer a treatment option for many patients unable to tolerate it.
The study, "Efficacy and Safety Results of Patients with HCV Genotype 2 or 3 Infection Treated with Ombitasvir/Paritaprevir/ritonavir and Sofosbuvir with or without Ribavirin (QUARTZ II-III)," was published online in the Journal of Viral Hepatology last month.
No comments:
Post a Comment